Increase in serum levels of phosphatidylserine-specific phospholipase A_(1) in COVID-19 patients

查看全文 作　　者：Takuya [1]Shimura;Makoto [1,2]Kurano;Koh [3]Okamoto;Daisuke [3]Jubishi;Kuniyuki [4]Kano;Koji [5]Igarashi;Satoshi [5]Shimamoto;Junken [4]Aoki;Kyoji [3]Moriya;Yutaka [1,2]Yatomi 机构地区：[1]Department of Clinical Laboratory,The University of Tokyo Hospital,Tokyo,Japan;[2]Department of Clinical Laboratory Medicine,Graduate School of Medicine,The University of Tokyo,Tokyo,Japan;[3]Department of Infectious Diseases,The University of Tokyo Hospital,Tokyo,Japan;[4]Department of Health Chemistry,Graduate School of Pharmaceutical Sciences,The University of Tokyo,Tokyo,Japan;[5]Bioscience Division,TOSOH Corporation,Kanagawa,Japan 出　　处：《Cellular & Molecular Immunology》索引2021年第18卷第9期,共3页 基　　金：This work was supported by Research Grants in the Natural Sciences from the Mitsubishi Foundation(MK);Leading Advanced Projects for medical innovation(LEAP)from AMED(JA and YY). 摘　　要：The development of novel drugs to overcome the current global coronavirus disease 2019(COVID-19)pandemic caused by severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)is an important task.Although antiviral agents have been investigated,one of the important goals of treatment is also to control the biological response to the infection.A series of elegant basic studies have revealed that lysophosphatidylserine(LysoPS)might play important roles in inflammation through three kinds of G protein-coupled receptors[1];LysoPS reportedly suppresses activation of T cells[2]and secretion of inflammatory cytokines from macrophages[3]and promotes phagocytosis of apoptotic cells,including apoptotic neutrophils,by macrophages[4]. 关 键 词：DRUGS INFLAMMATION ACUTE